{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:20:15Z","timestamp":1792783215116,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Don Panoz Pharmaceutical Innovation PhD Scholarship Programme at the School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin","id":[{"id":"https:\/\/ror.org\/02tyrky19","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-026-02229-6","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:31:07Z","timestamp":1790505067000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Helicobacter pylori eradication treatment dispensing in the Irish General Medical Services population from 2012 to 2022: a repeated cross-sectional analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1614-5456","authenticated-orcid":false,"given":"Marta","family":"Dobri\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6119-3676","authenticated-orcid":false,"given":"Carlos","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2861-7665","authenticated-orcid":false,"given":"Kathleen","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5564-2890","authenticated-orcid":false,"given":"Joseph","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2324-3382","authenticated-orcid":false,"given":"Deirdre","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3460-3590","authenticated-orcid":false,"given":"Sin\u00e9ad M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6037-4413","authenticated-orcid":false,"given":"Crist\u00edn","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"issue":"4","key":"2229_CR1","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1053\/j.gastro.2023.12.022","volume":"166","author":"YC Chen","year":"2024","unstructured":"Chen YC, Malfertheiner P, Yu HT, et al. Global prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022. Gastroenterology. 2024;166(4):605\u201319. https:\/\/doi.org\/10.1053\/j.gastro.2023.12.022.","journal-title":"Gastroenterology"},{"issue":"11","key":"2229_CR2","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1038\/s41591-024-03153-w","volume":"30","author":"KF Pan","year":"2024","unstructured":"Pan KF, Li WQ, Zhang L, et al. Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial. Nat Med. 2024;30(11):3250\u201360. https:\/\/doi.org\/10.1038\/s41591-024-03153-w.","journal-title":"Nat Med"},{"issue":"7","key":"2229_CR3","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/apt.14561","volume":"47","author":"M Zamani","year":"2018","unstructured":"Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868\u201376. https:\/\/doi.org\/10.1111\/apt.14561.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2229_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41572-023-00431-8","volume":"9","author":"P Malfertheiner","year":"2023","unstructured":"Malfertheiner P, Camargo MC, El-Omar E, et al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023;9(1):19. https:\/\/doi.org\/10.1038\/s41572-023-00431-8.","journal-title":"Nat Rev Dis Primers"},{"key":"2229_CR5","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. Vol. 61. Lyon: International Agency for Research on Cancer; 1994. 270 p. (IARC monographs on the evaluation of carcinogenic risks to humans). ISBN: 978-92-832-1261-4."},{"issue":"9","key":"2229_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/apt.14319","volume":"46","author":"Y Hu","year":"2017","unstructured":"Hu Y, Wan JH, Li XY, et al. Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori. Aliment Pharmacol Ther. 2017;46(9):773\u20139. https:\/\/doi.org\/10.1111\/apt.14319.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2229_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","volume":"153","author":"JKY Hooi","year":"2017","unstructured":"Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2017.04.022.","journal-title":"Gastroenterology"},{"issue":"10","key":"2229_CR8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.94522","volume":"17","author":"A Abdalla","year":"2025","unstructured":"Abdalla A, Singla S, Lakhani A, et al. Prevalence of histologically positive Helicobacter pylori infection among patients who underwent upper GI endoscopy at the University Hospital Limerick in 2023. Cureus. 2025;17(10):e94522. https:\/\/doi.org\/10.7759\/cureus.94522.","journal-title":"Cureus"},{"key":"2229_CR9","unstructured":"Hutchinson K, Lewis S, Zakharova A, et al. Helicobacter pylori testing in Ireland 2023\u20132024 [Poster] [Internet]. Poster presented at: 15th Infectious Diseases Society of Ireland Annual Scientific Meeting. 2024 [cited 27 Oct 2025]; D\u00fan Laoghaire, Ireland. Available from: https:\/\/idsociety.ie\/meetings\/2024-meeting\/submissions\/2024085\/eposter."},{"issue":"41","key":"2229_CR10","doi-asserted-by":"publisher","first-page":"9214","DOI":"10.3748\/wjg.v22.i41.9214","volume":"22","author":"DE Brennan","year":"2016","unstructured":"Brennan DE, Omorogbe J, Hussey M, et al. Molecular detection of Helicobacter pylori antibiotic resistance in stool vs biopsy samples. World J Gastroenterol. 2016;22(41):9214\u201321. https:\/\/doi.org\/10.3748\/wjg.v22.i41.9214.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2229_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/17474124.2019.1542299","volume":"13","author":"JY Wu","year":"2019","unstructured":"Wu JY, Lee YC, Graham DY. The eradication of Helicobacter pylori to prevent gastric cancer: a critical appraisal. Expert Rev Gastroenterol Hepatol. 2019;13(1):17\u201324. https:\/\/doi.org\/10.1080\/17474124.2019.1542299.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"11","key":"2229_CR12","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1136\/gutjnl-2025-336027","volume":"74","author":"JM Liou","year":"2025","unstructured":"Liou JM, Malfertheiner P, Hong TC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: Taipei global consensus II. Gut. 2025;74(11):1767\u201391. https:\/\/doi.org\/10.1136\/gutjnl-2025-336027.","journal-title":"Gut"},{"issue":"9","key":"2229_CR13","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1038\/s41591-025-03793-6","volume":"31","author":"JY Park","year":"2025","unstructured":"Park JY, Georges D, Alberts CJ, et al. Global lifetime estimates of expected and preventable gastric cancers across 185\u00a0countries. Nat Med. 2025;31(9):3020\u20137. https:\/\/doi.org\/10.1038\/s41591-025-03793-6.","journal-title":"Nat Med"},{"issue":"3","key":"2229_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36\u00a0cancers in 185\u00a0countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"2229_CR15","unstructured":"Park JY, editor. Population-based Helicobacter pylori screen-and-treat strategies for gastric cancer prevention: guidance on implementation. Lyon: International Agency for Research on Cancer; 2025. (IARC Working Group Reports; no. 12). ISBN: 978-92-832-4528-5."},{"key":"2229_CR16","doi-asserted-by":"publisher","unstructured":"OECD. EU country cancer profile: Ireland 2023. Paris: OECD Publishing; 2023. (EU Country Cancer Profiles). ISBN: 978-92-64-59333-6. https:\/\/doi.org\/10.1787\/f31164f8-en.","DOI":"10.1787\/f31164f8-en"},{"key":"2229_CR17","doi-asserted-by":"publisher","first-page":"1740221","DOI":"10.3389\/fgstr.2026.1740221","volume":"5","author":"O Casey","year":"2026","unstructured":"Casey O, Dobric M, Kelly O, et al. The importance of Helicobacter pylori eradication: a narrative review. Front Gastroenterol (Lausanne). 2026;5:1740221. https:\/\/doi.org\/10.3389\/fgstr.2026.1740221.","journal-title":"Front Gastroenterol (Lausanne)"},{"issue":"9","key":"2229_CR18","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","volume":"71","author":"P Malfertheiner","year":"2022","unstructured":"Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut. 2022;71(9):1724\u201362. https:\/\/doi.org\/10.1136\/gutjnl-2022-327745.","journal-title":"Gut"},{"issue":"1","key":"2229_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00042737-199701000-00002","volume":"9","author":"P Malfertheiner","year":"1997","unstructured":"Malfertheiner P, M\u00e9graud F, O\u02bcMorain C, et al. Current European concepts in the management of Helicobacter pylori infection\u2014the Maastricht consensus report. Eur J Gastroenterol Hepatol. 1997;9(1):1\u20132. https:\/\/doi.org\/10.1097\/00042737-199701000-00002.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"2229_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1046\/j.1365-2036.2002.01169.x","volume":"16","author":"P Malfertheiner","year":"2002","unstructured":"Malfertheiner P, M\u00e9graud F, O\u2019Morain C, et al. Current concepts in the management of Helicobacter pylori infection\u2014The maastricht 2\u20132000 consensus report. Aliment Pharmacol Ther. 2002;16(2):167\u201380. https:\/\/doi.org\/10.1046\/j.1365-2036.2002.01169.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2229_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","volume":"66","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain C, et al. Management of Helicobacter pylori infection\u2014the Maastricht V\/Florence consensus report. Gut. 2017;66(1):6\u201330. https:\/\/doi.org\/10.1136\/gutjnl-2016-312288.","journal-title":"Gut"},{"issue":"6","key":"2229_CR22","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/gut.2006.101634","volume":"56","author":"P Malfertheiner","year":"2007","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the maastricht III consensus report. Gut. 2007;56(6):772\u201381. https:\/\/doi.org\/10.1136\/gut.2006.101634.","journal-title":"Gut"},{"issue":"5","key":"2229_CR23","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","volume":"61","author":"P Malfertheiner","year":"2012","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA, et al. Management of Helicobacter pylori infection\u2014the Maastricht IV\/Florence consensus report. Gut. 2012;61(5):646\u201364. https:\/\/doi.org\/10.1136\/gutjnl-2012-302084.","journal-title":"Gut"},{"issue":"8","key":"2229_CR24","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1097\/MEG.0000000000002796","volume":"36","author":"SM Smith","year":"2024","unstructured":"Smith SM, Boyle B, Buckley M, et al. The second Irish Helicobacter pylori working group consensus for the diagnosis and treatment of Helicobacter pylori infection in adult patients in Ireland. Eur J Gastroenterol Hepatol. 2024;36(8):1000\u20139. https:\/\/doi.org\/10.1097\/MEG.0000000000002796.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"2229_CR25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/MEG.0000000000000822","volume":"29","author":"S Smith","year":"2017","unstructured":"Smith S, Boyle B, Brennan D, et al. The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. Eur J Gastroenterol Hepatol. 2017;29(5):552\u20139. https:\/\/doi.org\/10.1097\/MEG.0000000000000822.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2229_CR26","unstructured":"Health Service Executive. HSE Community Guidelines for Antibiotic Prescribing [Internet]. 2021 [cited 24 Jan 2025]. Helicobacter pylori treatment. Available from: https:\/\/www.hse.ie\/eng\/services\/list\/2\/gp\/antibiotic-prescribing\/conditions-and-treatments\/gastro\/helicobacter-pylori\/."},{"issue":"9","key":"2229_CR27","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","volume":"119","author":"WD Chey","year":"2024","unstructured":"Chey WD, Howden CW, Moss SF, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024;119(9):1730\u201353. https:\/\/doi.org\/10.14309\/ajg.0000000000002968.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2229_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/gutjnl-2020-321372","volume":"70","author":"OP Nyssen","year":"2021","unstructured":"Nyssen OP, Bordin D, Tepes B, et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5\u00a0years and 21 533\u00a0patients. Gut. 2021;70(1):40\u201354. https:\/\/doi.org\/10.1136\/gutjnl-2020-321372.","journal-title":"Gut"},{"issue":"8","key":"2229_CR29","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/j.1572-0241.2007.01393.x","volume":"102","author":"WD Chey","year":"2007","unstructured":"Chey WD, Wong BCY. Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808\u201325. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01393.x.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"2229_CR30","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/antibiotics14070680","volume":"14","author":"SM Smith","year":"2025","unstructured":"Smith SM, Nyssen OP, FitzGerald R, et al. First-line prescriptions and effectiveness of Helicobacter pylori eradication treatment in Ireland over a 10-year period: data from the European Registry on Helicobacter pylori management (Hp-EuReg). Antibiotics (Basel). 2025;14(7):680. https:\/\/doi.org\/10.3390\/antibiotics14070680.","journal-title":"Antibiotics (Basel)"},{"issue":"4","key":"2229_CR31","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008.","journal-title":"J Clin Epidemiol"},{"key":"2229_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3532","volume":"363","author":"SM Langan","year":"2018","unstructured":"Langan SM, Schmidt SA, Wing K, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ. 2018;363:k3532. https:\/\/doi.org\/10.1136\/bmj.k3532.","journal-title":"BMJ"},{"key":"2229_CR33","unstructured":"Department of Health. Health in Ireland: Key Trends 2024 [Internet]. Government of Ireland; 2025 [cited 16 Oct 2025]. Available from: https:\/\/www.gov.ie\/en\/department-of-health\/collections\/health-in-ireland-key-trends-2024\/."},{"key":"2229_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.12688\/hrbopenres.13622.2","volume":"5","author":"M Mattsson","year":"2023","unstructured":"Mattsson M, Flood M, Wallace E, et al. Eligibility rates and representativeness of the general medical services scheme population in Ireland 2016\u20132021: a methodological report. HRB Open Res. 2023;5:67. https:\/\/doi.org\/10.12688\/hrbopenres.13622.2.","journal-title":"HRB Open Res."},{"key":"2229_CR35","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. ATC\/DDD [Internet]. Norwegian Institute of Public Health; 2022 [cited 12 Dec 2025]. ATC\/DDD Index 2022. Available from: https:\/\/atcddd.fhi.no\/atc_ddd_index\/."},{"key":"2229_CR36","doi-asserted-by":"publisher","unstructured":"The pandas development team. pandas v2.1.1. 2023. https:\/\/doi.org\/10.5281\/zenodo.8364959.","DOI":"10.5281\/zenodo.8364959"},{"key":"2229_CR37","doi-asserted-by":"publisher","unstructured":"McKinney W. Data structures for statistical computing in Python. In: Proceedings of the 9th Python in Science Conference. 2010. p. 56\u201361. https:\/\/doi.org\/10.25080\/Majora-92bf1922-00a.","DOI":"10.25080\/Majora-92bf1922-00a"},{"issue":"5","key":"2229_CR38","first-page":"932","volume":"112","author":"L O\u2019Mahony","year":"2019","unstructured":"O\u2019Mahony L, Yelverton E. Prescribing of proton pump inhibitors in an Irish general practice. Ir Med J. 2019;112(5):932.","journal-title":"Ir Med J"},{"key":"2229_CR39","unstructured":"R Core Team. R: a language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2024 [cited 26 Oct 2025]. Available from: https:\/\/www.R-project.org\/."},{"key":"2229_CR40","unstructured":"Health Service Executive. Frequently asked questions [Internet]. [cited 7 Sep 2026]. Available from: https:\/\/hseresearch.ie\/research-ethics\/frequently-asked-questions\/."},{"issue":"9","key":"2229_CR41","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.3390\/children9091359","volume":"9","author":"R Borka Balas","year":"2022","unstructured":"Borka Balas R, Meli\u021b LE, M\u0103rginean CO. Worldwide prevalence and risk factors of Helicobacter pylori infection in children. Children (Basel). 2022;9(9):1359. https:\/\/doi.org\/10.3390\/children9091359.","journal-title":"Children (Basel)"},{"issue":"5","key":"2229_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12914","volume":"27","author":"M Chen","year":"2022","unstructured":"Chen M, Bair M, Chen P, et al. Declining trends of prevalence of Helicobacter pylori infection and incidence of gastric cancer in Taiwan: an updated cross-sectional survey and meta-analysis. Helicobacter. 2022;27(5):e12914. https:\/\/doi.org\/10.1111\/hel.12914.","journal-title":"Helicobacter"},{"issue":"17","key":"2229_CR43","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMcp1001110","volume":"362","author":"KE McColl","year":"2010","unstructured":"McColl KE. Helicobacter pylori infection. N Engl J Med. 2010;362(17):1597\u2013604. https:\/\/doi.org\/10.1056\/NEJMcp1001110.","journal-title":"N Engl J Med"},{"key":"2229_CR44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.canep.2019.04.003","volume":"60","author":"MP Curado","year":"2019","unstructured":"Curado MP, De Oliveira MM, De Ara\u00fajo FM. Prevalence of Helicobacter pylori infection in Latin America and the Caribbean populations: a systematic review and meta-analysis. Cancer Epidemiol. 2019;60:141\u20138. https:\/\/doi.org\/10.1016\/j.canep.2019.04.003.","journal-title":"Cancer Epidemiol"},{"issue":"7","key":"2229_CR45","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.dld.2017.03.019","volume":"49","author":"A Ibrahim","year":"2017","unstructured":"Ibrahim A, Morais S, Ferro A, et al. Sex-differences in the prevalence of Helicobacter pylori infection in pediatric and adult populations: systematic review and meta-analysis of 244 studies. Dig Liver Dis. 2017;49(7):742\u20139. https:\/\/doi.org\/10.1016\/j.dld.2017.03.019.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"2229_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1523-5378.2011.00894.x","volume":"17","author":"DM Queiroz","year":"2012","unstructured":"Queiroz DM, Carneiro JG, Braga-Neto MB, et al. Natural history of Helicobacter pylori infection in childhood: eight-year follow-up cohort study in an urban community in northeast of Brazil. Helicobacter. 2012;17(1):23\u20139. https:\/\/doi.org\/10.1111\/j.1523-5378.2011.00894.x.","journal-title":"Helicobacter"},{"issue":"2","key":"2229_CR47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4103\/jopcs.jopcs_3_21","volume":"2","author":"S Bhattacharya","year":"2021","unstructured":"Bhattacharya S, Saleem SM. Neglected diseases in the era of COVID-19 pandemic: it\u2019s the right time to act together. J Prim Care Spec. 2021;2(2):25\u20136. https:\/\/doi.org\/10.4103\/jopcs.jopcs_3_21.","journal-title":"J Prim Care Spec"},{"issue":"6","key":"2229_CR48","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1007\/s11845-024-03810-6","volume":"193","author":"ME O\u2019Callaghan","year":"2024","unstructured":"O\u2019Callaghan ME, Glynn LG. Effects of COVID-19 on Irish general practice activity from 2019 to 2021: a retrospective analysis of 500,000 consultations using electronic medical record data. Ir J Med Sci. 2024;193(6):2835\u201341. https:\/\/doi.org\/10.1007\/s11845-024-03810-6.","journal-title":"Ir J Med Sci"},{"key":"2229_CR49","unstructured":"Primary Care Reimbursement Service. Statistical analysis of claims and payments [Internet]. Dublin: Health Service Executive; 2022. [cited 25 Oct 2025]. Available from: https:\/\/about.hse.ie\/api\/v2\/download-file\/file_based_publications\/PCRS_Statistical_Analysis_of_Claims_and_Payments_2022.pdf."},{"issue":"1","key":"2229_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/gutjnl-2024-332804","volume":"74","author":"L Olmedo","year":"2025","unstructured":"Olmedo L, Calvet X, Gen\u00e9 E, et al. Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg). Gut. 2025;74(1):15\u201325. https:\/\/doi.org\/10.1136\/gutjnl-2024-332804.","journal-title":"Gut"},{"key":"2229_CR51","unstructured":"Health Service Executive, Primary Care Reimbursement Service. Exempt medicinal products (unlicensed medicines) arrangements [Circular] [Internet]. Dublin: Health Service Executive; 2023 [cited 10 Feb 2025]. Circular no.: 012\/23. Available from: https:\/\/www.hse.ie\/eng\/staff\/pcrs\/circulars\/pharmacy."},{"key":"2229_CR52","unstructured":"Health Products Regulatory Authority. Pylera 140\u00a0mg\/125\u00a0mg\/125\u00a0mg Capsules [Internet]. [cited 31 Oct 2025]. Available from: https:\/\/www.hpra.ie\/find-a-medicine\/for-human-use\/withdrawn-medicines\/details\/30316."},{"issue":"2","key":"2229_CR53","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.26420\/AustinJInfectDis.2022.1069","volume":"9","author":"I Jukic","year":"2022","unstructured":"Jukic I, Vukovic J, Modun D, et al. Historical overview of the Maastricht consensus reports for the management of Helicobacter pylori infection. Where are we today? Austin J Infect Dis. 2022;9(2):1069. https:\/\/doi.org\/10.26420\/AustinJInfectDis.2022.1069.","journal-title":"Austin J Infect Dis"},{"issue":"5","key":"2229_CR54","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","volume":"155","author":"A Savoldi","year":"2018","unstructured":"Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155(5):1372-1382.e17. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.007.","journal-title":"Gastroenterology"},{"issue":"10","key":"2229_CR55","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1136\/gutjnl-2021-324032","volume":"70","author":"F Megraud","year":"2021","unstructured":"Megraud F, Bruyndonckx R, Coenen S, et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021;70(10):1815\u201322. https:\/\/doi.org\/10.1136\/gutjnl-2021-324032.","journal-title":"Gut"},{"issue":"3","key":"2229_CR56","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/microorganisms14030704","volume":"14","author":"TJ Butler","year":"2026","unstructured":"Butler TJ, Molloy S, Douglas A, et al. High levels of Helicobacter pylori antimicrobial resistance in Ireland\u2014a multicentre study. Microorganisms. 2026;14(3):704. https:\/\/doi.org\/10.3390\/microorganisms14030704.","journal-title":"Microorganisms"},{"issue":"8","key":"2229_CR57","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3390\/antibiotics14080757","volume":"14","author":"C Costigan","year":"2025","unstructured":"Costigan C, Comerford M, Whitmarsh R, et al. Bismuth quadruple therapy with doxycycline is an effective first-line therapy for Helicobacter pylori in an Irish cohort. Antibiotics (Basel). 2025;14(8):757. https:\/\/doi.org\/10.3390\/antibiotics14080757.","journal-title":"Antibiotics (Basel)"},{"issue":"2","key":"2229_CR58","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5639\/gabij.2022.1102.011","volume":"11","author":"FJ Pi\u00f1eiro","year":"2022","unstructured":"Pi\u00f1eiro FJ, Fern\u00e1ndez Arg\u00fcelles RA. A case study of AstraZeneca\u2019s omeprazole\/esomeprazole chiral switch strategy. GaBI J. 2022;11(2):57\u201364. https:\/\/doi.org\/10.5639\/gabij.2022.1102.011.","journal-title":"GaBI J"},{"key":"2229_CR59","unstructured":"Health Service Executive, Medicines Management Programme. Preferred drugs: proton pump inhibitors for the treatment of gastro-oesophageal reflux disease. Version 1.0 [Internet]. Dublin: Health Service Executive; 2019. [cited 11 Mar 2025]. Available from: https:\/\/healthservice.hse.ie\/documents\/8065\/MMP_Evaluation_Report_Preferred_Drugs_-_PPIs.pdf."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02229-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02229-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02229-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:01:40Z","timestamp":1790550100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02229-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":59,"alternative-id":["2229"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02229-6","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"assertion":[{"value":"1 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.B. has received funding from Novartis and IQVIA for unrelated research. The remaining authors declare no competing interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In a\n                      cc\n                      ordance with the HSE research ethics guidance, formal Research Ethics Committee (REC) review was not required for this study as it relied entirely on the secondary analysis of fully anonymised data [\n                      \n                      ].","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}